期刊文献+

融合蛋白GGH粉针剂制备工艺研究

Study on the Preparation Technology of Injectable Powder of Fusion Protein GGH
原文传递
导出
摘要 目的:建立高效液相色谱法测定融合蛋白GGH原料和注射用粉针剂含量的方法,筛选制备粉针剂的辅料和p H,进行6个月的长期稳定性试验。方法:高效液相色谱采用Waters DELTA PAK C18色谱柱,流动相为乙腈和水,梯度洗脱20min,检测波长280nm。根据粉针剂的外形、复溶性、稳定性和活性保留率筛选填充剂及p H。结果:GGH在0.2~1.6mg/ml范围内线性关系良好,可用此方法进行制剂的含量检测;选用4%的甘露醇作为填充剂并调节p H为5.5,可以制备性质较为稳定的GGH冻干粉针剂。结论:可采用含量和纯度检测结合外观性状观察法用于粉针剂的制备工艺筛选,为申报新药提供参考。 Objective: To establish an HPLC method for the determination of content of GGH and its injectable powder. To screen the supplementary materials and p H and study on the stability for 6 months.Methods: The Waters DELTA PAK C18 column was used,and the mobile phase was acetonitrile and water with gradient elution for 20 minutes. The detection wavelength was 280 nm. Screened the fillers and p H according to the powder shape,solubility,stability and activity. Results: The calibration curve was linear in the range of0. 2 ~ 1. 6mg / ml,R^2= 0. 999,which could be used to the content detection of the powder. Four percent mannitol and p H5. 5 were selected to prepare the GGH injectable powder with stable quality. Conclusions: The determination of purity and activity,together with the appearance observation method,could be used for the study of preparation technology,which provided references for the application of new drugs.
机构地区 江南大学药学院
出处 《中国生物工程杂志》 CAS CSCD 北大核心 2016年第11期48-53,共6页 China Biotechnology
基金 江苏省科技支撑(社会发展)计划资助项目(BE2009629)
关键词 融合蛋白 粉针剂 含量测定 制备工艺 Fusion protein Injectable powder Determination of content Preparation technology
  • 相关文献

参考文献3

二级参考文献33

  • 1赵传珍,李萍.静脉输液避光套的制作及应用[J].护理研究(下半月),2004,18(12):2171-2171. 被引量:4
  • 2章翰 李天宪 等.单个核细胞内cAMP提取方法的研究[J].中国免疫学杂志,1988,4:42-3.
  • 3舍斯基,韦勒.药用辅料手册(第四版)[M].北京:化学工业出版社,2005.262-264.
  • 4Susumu S, Manabu M, Shigeki A, et al. The effects of amylin on insulin secretion from Rin m5F cells and glycogen synthesis and lipogenesis in rat primary cultured hepatocytes. Diabetes Research and Clinical Practice, 1992(15):77-84.
  • 5Matias I, Gonthier M P, Orlando P, et al. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. Journal of Clinical Endocrinology and Metabolism, 2006, 91(8):3171-3180.
  • 6Santina B, Nicoletta B, Cesare U, et al. Abscisic acid is an endogenous stimulator of insulin release from human pancreatic islets with cyclic ADP ribose as second messenger. Journal of Biological Chemistry, 2008, 11:32188-32197.
  • 7Narita M, Murata T, Shimizu K, et al. A role for cyclic nucleotide phosphodiesterase 4 in regulation of the growth of human malignant melanoma cells. Oncology Reports, 2007, 17:1133-1139.
  • 8Gallwitz B, Ropeter T, Morys-Wortmann C, et al. GLP-1-analogues resistant to degradation by dipeptidyl-peptidase IV in vitro. Regulatory Peptides, 2000, 86:103-111.
  • 9SUZUKI Y,ZHANG H,SAITO N,et al. Glucagon-like peptide 1 activates protein kinase C through Ca2 -dependent activation of phospholipase C in insulin-secreting cells[ J ]. Biol Chem,2006, 281 (39) :28499 - 28507.
  • 10D'ALESSIO DA, KAHN SE, LEUSNER CR, et al. Glucagon- like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose dis- posal[J]. Clin lnvet,1994, 93(5) :2263.

共引文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部